| |
|
|
|
-, San Diego Sheraton Hotel & Marina, San Diego, CA
April 26-28, 2004
IBC’s Inaugural Conference on Early Development of Biotherapeutics: Successful Approaches for Managing Immunogenicity and Comparability, Interpreting Regulations and Guidances, and Implementing Process Changes has been developed to address the most important issues in the development of biotherapeutics by providing case studies, presentations by FDA regulators and detailed product development presentations by industry experts. IBC’s Inaugural Conference on Early Development of Biotherapeutics is conveniently held concurrently with IBC’s 8th International Intensive Symposium on Biological Assay Development & Validation. This creates a rare opportunity to share perspectives and strategies with hundreds of leaders in the industry through shared sessions featuring 5 case studies, luncheons, and a cocktail reception. To register or view full details for IBC’s Inaugural Conference on Early Development of Biotherapeutics, visit www.LifeSciencesInfo.com/3071. To register or view full details for IBC’s 8th International Intensive Symposium on Biological Assay Development & Validation, visit www.LifeSciencesInfo.com/3011.
|
|
|
|
|
|
|
|
Organized by:
|
|
IBC Life Sciences |
|
|
Invited Speakers:
|
|
Featured Presenters: Anthony R. Mire-Sluis, Ph.D., CDER, US FDA
Robert L. Garnick, Ph.D., Genentech, Inc.
Fred G. Bader, Ph.D., Centocor
Don A. Baker, Ph.D., Baxter Healthcare Corp.
Russ Middaugh, Ph.D., University of Kansas
Dean Pettit, Ph.D., Amgen, Inc.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
-
|
|
|
|
|
|
|
|
Registration:
|
|
Online: www.LifeSciencesInfo.com/3071
Phone: 508-616-5550 x1004
Fax: 508-616-5522
E-mail: reg@ibcusa.com
|
|
|
E-mail:
|
|
reg@ibcusa.com
|
|
|
|
|
|
|
|
|